<DOC>
	<DOCNO>NCT00261911</DOCNO>
	<brief_summary>The purpose study assess effectiveness sibutramine weight loss , reduction body size improvement metabolic risk factor safety obese adolescent .</brief_summary>
	<brief_title>A Study Sibutramine Overweight Adolescents Assess Weight Loss Safety .</brief_title>
	<detailed_description />
	<mesh_term>Sibutramine</mesh_term>
	<criteria>Obese adolescent male females good general health lower limit inclusion BMI 2 unit U.S. weight mean 95th percentile weight base age gender BMI 44 kg/m2 , age 12 16 year randomization . ( Efforts direct obtain study population comprise 50 % 75 % female least 30 % African Americans across study . Each site enroll similar number patient age within 12 16 year old age range . ) Both patient legal guardian/parent must able communicate meaningfully investigator , legally competent , provide write informed consent/assent . All patient must exhibit sufficient comprehension write material able follow diet exercise recommendation , complete write behavioral assessment . For female childbearing potential , negative pregnancy test require prior study inclusion . Female patient , sexually active , must use adequate contraceptive precaution ( i.e. , oral contraceptive , approve hormonal implant , intrauterine device , diaphragm spermicide , condom spermicide ) . Oral contraceptive use permit use least 3 month start study medication . A serum pregnancy test , must negative , require female . The patient must screen baseline visit mean systolic blood pressure &lt; =130 mm Hg , diastolic blood pressure &lt; =85 mm Hg , pulse rate &lt; =95 beat per minute . Treated hypertensive allow study medication stable least 3 month . The patient must history anorexia nervosa . The patient must history clinically significant cardiac disease , congenital heart disease , clinically significant abnormal cardiac condition , know clinically significantly abnormal ECG . Specifically excluded condition include coronary artery disease , clinically significant cardiac arrhythmia , congestive heart failure . The patient must history stroke . The patient must history asthma require chronic oral corticosteroid therapy . A short course ( &lt; 7 day ) oral corticosteroid medication permit acute exacerbation . The patient must history narrow angle glaucoma . The patient must history gallstone unless status post cholecystectomy . The patient must history seizure exception childhood febrile seizure . The patient must evidence possible renal dysfunction ( creatinine &gt; 1.7 mg/dL ) hepatic dysfunction ( ALT &gt; 50 IU/L , bilirubin &gt; 1.0 mg/dL ) . Patients must evidence active chronic Hepatitis B C infection . The patient must use follow medication time study : monoamine oxidase inhibitor ( e.g. , furazolidone , phenelzine , procarbazine hydrochloride , selegiline ) , antidepressant agent ( include use antidepressant agent 2 week 90 day period prior screen ) , lithium , serotonin reuptake inhibitor , certain opioids ( dextromethorphan , meperidine , pentazocine , fentanyl ) , prescribe overthecounter weight loss agent , centrally act appetite suppressant , tryptophan , sympathomimetics , serotonergic antimigraine agent ( include sumatriptan succinate , dihydroergotamine , etc . ) medication , opinion Investigator , may pose harm patient , obscure effect study medication interfere process drug absorption , distribution , metabolism , excretion ( i.e. , enzyme inducer enzyme inhibitor ) . Patients may take antidepressant purpose enter study . The patient parent/legal guardian must history alcohol drug addiction substance abuse within previous two year . Patients must 95th percentile gender age follow category Screening , assess Child Behavior CheckList : `` think problem '' , `` delinquent behavior '' , `` aggressive behavior '' , `` attention problem '' . The patient must tscore great 65 ( significantly average ) total Child Depression Inventory score . The patient must participate rigorous , structured weight loss program 2 week within past 6 month prior screen . Continuing participation less rigorous program Weight Watchers allow ; however , patient must participant least 6 month prior screen allow study . The patient must participate investigational drug study within thirty ( 30 ) day prior screen . The patient must use prescription OTC ( herbal ) weight control medication two ( 2 ) week 180 day period immediately precede screen . In addition , medication allow trial . The patient must previously patient/subject sibutramine trial otherwise used sibutramine . Pregnancy Pathophysiologic genetic syndrome associate obesity ( Cushing 's syndrome , Turner 's syndrome , PraderWilli syndrome ; etc . ) Diabetes mellitus ( FBG great equal 126 mg/dL ) Untreated hypothyroidism ( TSH great 4.0 mU/L second generation test ) Malignancy Patient must drug screen positive recreational drug . Coagulopathies bleed disorder Gastric bypass surgical procedure potential interfere absorption study medication , gastric restrictive surgery . Major psychiatric illness either patient patient 's legal guardian/parent ( ) bipolar disorder , ADD , major depression , bulimia , schizophrenia , psychosis ; etc . Failure maintain minimum level academic achievement previous 6 month prior screen ( patient exclude receive multiple fail grades school ) . Any severe medical psychiatric disorder precludes participation .</criteria>
	<gender>All</gender>
	<minimum_age>12 Years</minimum_age>
	<maximum_age>16 Years</maximum_age>
	<verification_date>August 2007</verification_date>
	<keyword>Meridia</keyword>
	<keyword>Sibutramine</keyword>
	<keyword>Obesity</keyword>
	<keyword>Adolescent</keyword>
	<keyword>BMI</keyword>
</DOC>